BioXcel Therapeutics, Inc. Revenue 2022–2025
BioXcel Therapeutics, Inc. annual/quarterly revenue history and growth rate from 2022 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- BioXcel Therapeutics, Inc. revenue for the quarter ending March 31, 2026 was 206000, a 22.62% increase year-over-year.
- BioXcel Therapeutics, Inc. revenue for the twelve months ending March 31, 2026 was 592000, a 73.58% decrease year-over-year.
- BioXcel Therapeutics, Inc. annual revenue for 2025 was 642000, a 71.67% decrease from 2024.
- BioXcel Therapeutics, Inc. annual revenue for 2024 was 2.3 M, a 64.20% increase from 2023.
- BioXcel Therapeutics, Inc. annual revenue for 2023 was 1.4 M, a 268.00% increase from 2022.
- BioXcel Therapeutics, Inc. annual revenue for 2022 was 375000.
BioXcel Therapeutics, Inc. (BTAI) — Frequently Asked Questions
BioXcel Therapeutics, Inc. (BTAI) is a publicly traded US company. It has a market capitalization of $13M. In fiscal 2025 it reported revenue of $642,000 and net income of -$70M. Explore BTAI's stock price, financial statements, earnings history, margins and key ratios below.
What is BioXcel Therapeutics, Inc.'s market cap?
BioXcel Therapeutics, Inc. (BTAI) has a market capitalization of $13M.
What is the BTAI stock price?
BTAI trades at $1.09 (+1.87% on the day).
How much revenue does BioXcel Therapeutics, Inc. make?
BioXcel Therapeutics, Inc. reported revenue of $642,000 in fiscal 2025.
Is BTAI profitable?
In fiscal 2025, BioXcel Therapeutics, Inc. reported net income of -$70M.